Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment.

ABSTRACT:

Background

Treatment-resistant depression (TRD) affects 30-50% of patients with major depressive disorder (MDD). Electroconvulsive therapy (ECT) and sub-anesthetic ketamine treatment can relieve TRD, yet their antidepressant mechanisms remain unclear. Peripheral blood gene expression offers a non-invasive proxy to examine potential treatment-response biomarkers.

Methods

We conducted a transcriptome analysis on peripheral blood samples from individuals with TRD undergoing ECT (N=37) or serial ketamine infusions (N=60), and non-depressed controls (N=35). Samples were collected at baseline and at multiple follow-up time points. Differential gene expression (DGE) at the single gene and network level identified transcriptional changes and co-regulated gene modules associated with

SUBMITTER: Zavaliangos-Petropulu A 

PROVIDER: S-EPMC12324635 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature